References
- Ge W , ChenC, WuNet al. Hedgehog pathway inhibitor real-world treatment patterns in patients with basal cell carcinoma: a claims-based analysis. Fut. Oncol.18(23), 2561–2572 (2022).
- Dréno B , KunstfeldR, HauschildRet al. Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial. Lancet Oncol.18(3), 404–412 (2017).
- Sekulic A , MigdenMR, Basset-SeguinNet al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer17(1), 332 (2017).
- Lear JT , MigdenMR, LewisKDet al. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. J. Eur. Acad. Dermatol. Venereol.32(3), 372–381 (2018).
- Basset-Séguin N , HauschildA, KunstfeldRet al. Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open-label trial. Eur. J. Cancer86, 334–348 (2017).
- Gutzmer R , SchulzeH-J, HauschildAet al. Effectiveness, safety and utilization of vismodegib in locally advanced basal cell carcinoma under real-world conditions in Germany-The non-interventional study NIELS. J. Eur. Acad. Dermatol. Venereol.35(8), 1678–1685 (2021).
- Cowey L , ChenC-I, AguilarKMet al. Real-World Treatment Patterns and Outcomes Among Patients with Basal Cell Carcinoma Following First-Line Hedgehog Inhibitor Discontinuation. Dermatol. Ther. (Heidelb.)12(5), 1211–1224 (2022).
- De Giorgi V , ScarfìF, TraneFet al. Treatment of advanced basal cell carcinoma with hedgehog pathway inhibitors: a multidisciplinary expert meeting. Cancers (Basel)13(22), 5706 (2021).
- Stratigos AJ , SekulicA, PerisKet al. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncol.22(6), 848–857 (2021).